WeightWatchers expands Med+ clinical program nationwide through LillyDirect partnership

WW International has expanded its Med+ clinical program nationwide through a partnership with LillyDirect, Eli Lilly's direct-to-consumer pharmacy channel ^[1]. The move is part of the company's post-bankruptcy shift away from its legacy behavioral weight-loss business and toward care built around GLP-1 medications ^[1].

Med+ membership costs $25 a month for the first two months on a 12-month plan, then $74 a month, with medication billed separately ^[2]. That introductory rate ends September 8, 2026 at 11:59 p.m. PDT ^[2]. WW's news timeline also lists a LillyDirect partnership item dated June 4, 2026, while the research note describing the nationwide expansion is dated September 5, 2026; the timing difference is not explained ^[1].

What the program covers

WW prescribes FDA-approved brand medications only: Wegovy in injection and pill form, Zepbound, Saxenda, the Foundayo pill, metformin and naltrexone/bupropion, filled through mail-order partner Carepoint in Schaumburg, Illinois ^[2]. No compounded GLP-1 appears on any WW page, and third-party reviewers date WW's exit from compounded semaglutide to May 2025 ^[2].

Cash prices through LillyDirect for Zepbound are $299 for 2.5 mg, $399 for 5 mg and $449 for 7.5 to 15 mg, as a vial or KwikPen ^[2]. Those prices rise to $599 to $1,049 if a refill is delayed, and WW states the KwikPen is not eligible for insurance coverage ^[2]. The Wegovy pen is $199 for the first two fills for new patients through December 31, 2026, then $349, with the 7.2 mg dose at $399; the Wegovy pill runs $149, $199 or $299 depending on dose ^[2].

The business behind the expansion

WW's second-quarter 2026 revenue fell 22.7 percent year over year as the legacy behavioral business shrank, while the clinical segment integrating GLP-1 medications grew 30.4 percent annually ^[1]. A 2025 Chapter 11 restructuring eliminated more than $1.1 billion in debt and reduced the term loan from $1.6 billion to $423.6 million, leaving $101.5 million in unrestricted cash and adjusted gross margins above 73 percent ^[1].

About 20,000 members upgraded from the behavioral program to the clinical program in the first quarter of 2026, a roughly four-times revenue-per-user uplift, and the higher-priced Core+ tier posted its third consecutive quarter of sequential subscriber growth ^[1]. WW has operated with an interim leadership team since CEO Tara Comonte stepped down in April 2026 and had not named a permanent replacement as of the partnership announcement ^[1].

Why it matters for patients

The practical effect is that one program now combines prescribing by licensed clinicians with WW's food tracking, coaching and community, a structure WW markets as different from telehealth services that offer medication with lighter behavioral support ^[2]. Members must qualify based on BMI and health history, the same screening any prescribing provider applies ^[2].

Cost depends on the drug and whether you pay cash. A cash-pay member on the starting dose of Zepbound pays about $324 a month for the first two months ($25 membership plus $299 medication) and $373 after that; on Wegovy's introductory pen price, about $224 then $423 ^[2]. WW's insurance coordinators work with commercial plans only, not Medicare, Medicaid or Kaiser, and Medicare beneficiaries access GLP-1s separately through a $50-a-month Medicare GLP-1 Bridge running July 1, 2026 to December 31, 2027 ^[2].

WW reports an average 21 percent body-weight loss at 12 months among Med+ members taking a GLP-1, based on company data from about 3,250 patients that has not been peer reviewed ^[2]. The Zepbound label reports 20.9 percent mean weight loss at 72 weeks on the 15 mg dose in the SURMOUNT-1 trial ^[2]. Because WW's figure has no comparison group, it does not show that coaching adds to what the drug does on its own ^[2]. Member reviews collected by third-party sites put WW's Trustpilot rating at about 3.9 out of 5 across more than 1,660 reviews, with recurring complaints about billing that is easier to start than stop and variable wait times ^[2].

Because WW sells brand medications only, patients who want compounded versions will not find them here; across 14 providers tracked in September 2026, compounded semaglutide had a first-month median price of $197 and compounded tirzepatide $299 ^[2].

What happens next

The $25 introductory membership rate ends September 8, 2026 ^[2]. Wegovy's $199 first-two-fills pricing for new cash-paying patients runs through December 31, 2026, after which the pen price is $349 ^[2]. The Medicare GLP-1 Bridge program runs through December 31, 2027 and requires prior authorization ^[2]. WW had not named a permanent CEO as of the partnership announcement ^[1].